Clinical Software in Massachusetts

Sonio is a cloud-based AI-powered ultrasound reporting software platform specializing in OB-GYN and prenatal care. The platform integrates with ultrasound machines from all manufacturers to deliver FDA-cleared and CE-marked AI diagnostics, quality control, and automated reporting workflows. Key capabilities include Sonio Detect (AI-assisted anomaly detection), automated image management with intelligent view sorting, real-time quality control verification, visual checklists for exam completeness, integrated practice analytics, and seamless connectivity to EHRs, PACS, billing systems, and external providers via HL7/FHIR/eFAX. The platform enables sonographers and OB-GYNs to standardize reporting, improve diagnostic accuracy, reduce manual data entry, and enhance prenatal care access globally. Sonio operates on secure cloud or on-premise infrastructure with SOC2 Type II, HIPAA, ISO 13485, and GDPR compliance.

Associates of Cape Cod, Inc. (ACC) is a specialist manufacturer of endotoxin and glucan testing reagents, instrumentation, and software for pharmaceutical, biological product, and medical device manufacturers. The company's primary product portfolio centers on Limulus Amebocyte Lysate (LAL) reagents—derived from horseshoe crab blood—used to detect bacterial endotoxins in injectable pharmaceuticals, biologics, and medical devices. ACC also manufactures recombinant endotoxin testing (rBET) alternatives, including recombinant cascade reagents, positioning itself as a supplier of both traditional and next-generation pyrogen detection solutions. The Pyros® eXpress software platform provides integrated quantitative analysis and data management for endotoxin and glucan detection testing across glass tube and plate reader formats, with documented compatibility with Agilent BioTek Epoch 2 microplate readers. ACC operates a Contract Test Services (CTS) laboratory offering third-party endotoxin and glucan contamination testing. The company supports customers through free consultation, methodology guidance, and technical training. ACC maintains a demonstrated commitment to sustainability, including the Horseshoe Crab Sustainability Project (having reared and released over 1 million juvenile horseshoe crabs) and environmental responsibility in manufacturing. The company supplies the regulated biomedical testing market, serving manufacturers of injectable drugs, biologics, and medical devices requiring endotoxin testing for regulatory compliance (FDA, pharmacopeial).

Overjet is a dental AI software company providing an integrated platform for clinical decision support and administrative automation. The company develops FDA-cleared vision AI for x-ray analysis that detects disease and anatomical structures to improve diagnosis and case acceptance. Core products include Vision AI (x-ray analysis software), IRIS (AI-native dental imaging software with auto-populated templates and image enhancement), Dental Insurance Verification (automated coverage verification across 300+ payers with code-level breakdowns), and Voice AI Suite (unified clinical intelligence combining imaging insights with voice-to-text documentation and automated charting). The platform serves dentists, dental service organizations (DSOs), educators, and dental insurers. Overjet's technology streamlines clinical workflows, reduces administrative burden through automated insurance verification and charting, and improves patient understanding through AI visualizations. The company is trusted by major dental organizations including Dental Care Alliance, CoreDental, Jefferson Dental, Aligned Dental Partners, and others. Products integrate with existing dental practice management systems and consolidate imaging and AI capabilities without separate cloud storage fees. Regulatory clearance includes FDA approval for vision AI diagnostic capabilities.

Straumann Holding AG is a global leader in implant and restorative dentistry, headquartered in Basel, Switzerland, with a US presence. The company manufactures comprehensive dental implant systems, prosthetic solutions, regenerative biomaterials, and digital dentistry platforms for dental professionals, laboratories, and practices worldwide. Core product lines include the Straumann® dental implant systems (BLX, TLX, and proprietary designs), complemented by the iEXCEL™ performance system for implant placement and restoration. The company offers integrated digital solutions via the Straumann AXS™ platform, including intraoral scanners (SIRIOS™ X3), chairside 3D printing (Signature Midas by SprintRay), and software for smile design and practice management (Smilecloud, CareStack®). Regenerative offerings include the GalvoSurge® dental implant cleaning system for biofilm removal and surface decontamination. Guided surgical planning is enabled through Straumann Falcon™ navigation technology. The prosthetics portfolio encompasses abutments, bridges, and restoration components. Straumann also provides consumables (scanbodies, analogs, sleeves), healing components, and a full range of instruments and accessories. The company maintains ISO 13485 and FDA certification for its medical devices. Straumann distributes products globally through its own sales network and local partners, with dedicated eCommerce capability via the Straumann eShop. Training and education are central to the business model, offering accredited courses in implantology, digital workflows, and regenerative techniques. The company publishes scientific evidence through youTooth™ platform and maintains research-backed clinical protocols.

BEGO (Bremer Goldschlägererei Wilh. Herbst GmbH & Co.) is a Germany-based dental technology and implant solutions manufacturer offering comprehensive product lines spanning 3D printing, CAD/CAM solutions, dental implants, and conventional dental technology. The company specializes in digital dentistry workflows and supplies materials, equipment, software, and professional services to dental technicians and dental practices. 3D Printing Solutions: BEGO manufactures proprietary 3D printing resins including VarseoSmile TriniQ (a tooth-colored material for dentures and temporary restorations), VarseoSmile Crown plus (ceramic-filled hybrid for permanent crowns, inlays, onlays, veneers), VarseoSmile Temp, and VarseoWax materials for model and investment casting applications. The company provides compatibility guidance for major 3D printer systems. CAD/CAM Solutions: BEGO operates production facilities offering Selective Laser Melting (SLM), High Speed Cutting (HSC), CAD/Cast, and digital model production services. Core CAD/CAM materials include zirconium dioxide (BEGO Zirkon ST, Zirkon LT, KATANA, VITA systems), acrylics (PMMA multicolor, splint materials), non-precious and precious metal alloys (WIRONIUM RP series, Mediloy, Wirobond, Bio PontoStar, PontoLloyd), and glass ceramics (IPS e.max CAD). Applications include partial dentures, crowns, bridges, telescopic double crowns, implant prosthetics, digital dentures, orthodontic appliances, and splints. Dental Implant Systems: BEGO Semados implant platform includes RSX Pro Conical Connection, SCX Conical Connection, and RS/RSX/SC/SCX implant variants. The company offers implant prosthetics (abutments, healing posts, bridges, bar structures), guided surgical solutions (BEGO Guide surgical guides and planning systems), and regenerative materials (naturesQue bone grafts and membranes: SemOss B, MaxOss P, ColTect P, ColAid P). Digital Infrastructure: BEGO provides intraoral scanner integrations (Medit, 3Shape), CAD/CAM software (3Shape, exocad, proprietary BEGO software), order portals (BEGO CAD/CAM Orderportal, BEGO Guide portal), and customer support via TeamViewer and remote consultation. The company maintains a Scan and Design Centre and offers technical bulletins, declarations of conformity, and material libraries. Conventional Dental Technology: Work preparation, duplicating, modeling, embedding, casting alloys, laser cutting, and surface treatment supplies via BEGO eShop. The company holds relevant dental device certifications and maintains ISO compliance. BEGO operates production centers in Bremen, Germany, with international distribution networks and professional education/training programs for dental professionals.

Myriad Fiber Imaging Technologies is an ISO 13485-certified medical device manufacturer specializing in ultra-precision micro-endoscopy and visualization systems. Founded in 1995, the company designs and manufactures sub-1mm diameter fiberscopes, videoscopes, and CMOS imaging endoscopes ranging from 0.37mm to 5mm in diameter. MFI offers comprehensive OEM contract manufacturing, including electronic assembly, CMOS imaging systems, optical design, image processing, CNC machining, and micro-optics assembly. The company operates an 18,000 sq ft ISO-certified facility with 30+ years of technical expertise, serving primarily the medical sector (80% of business) alongside government, aerospace, and industrial applications. MFI is a U.S. distributor of Fujikura fiber optics and OmniVision CMOS sensors, providing both high-volume production and low-volume prototyping capabilities.

Foundation Medicine is a precision oncology diagnostics company specializing in comprehensive genomic profiling (CGP) and companion diagnostic testing for advanced cancer patients. The company develops and commercializes FDA-approved next-generation sequencing (NGS) based in vitro diagnostic tests, including FoundationOne®CDx (tissue-based) and FoundationOne®Liquid CDx (blood-based, circulating cell-free DNA). FoundationOne CDx analyzes 324 genes plus genomic signatures from formalin-fixed, paraffin-embedded (FFPE) tissue samples. FoundationOne Liquid CDx analyzes 324 genes using plasma specimens, reporting short variants in 311 genes, rearrangements in 8 genes, and copy number alterations in 3 genes. Foundation Medicine also offers FoundationOne Heme testing and IHC (immunohistochemistry) services. The company serves three core markets: healthcare providers and oncologists seeking biomarker-driven treatment selection; biopharmaceutical and research partners requiring companion diagnostic development, clinical trial support, and regulatory expertise across the drug development lifecycle; and patients seeking personalized cancer treatment guidance. Foundation Medicine operates a global laboratory with comprehensive EMR integration capabilities and provides decision support services and educational resources to clinicians. The company has delivered over 1.5 million genomic profiling reports and holds more than 50% of all approved US companion diagnostic indications for NGS testing. Services span discovery and translational research, clinical development and CDx strategy, and access and commercialization support. The company is FDA-regulated and maintains rigorous quality standards for molecular diagnostics.

Activ Surgical is a Boston-based digital surgery company specializing in hardware-agnostic surgical software and intraoperative imaging technologies designed to enhance visualization and reduce surgical errors. The company's flagship product, ActivSight™ Intelligent Light, is FDA-cleared and integrates with existing laparoscopic and robotic surgical systems to provide real-time visualization of blood flow and tissue perfusion. ActivSight offers surgeons critical physiological insights invisible to the naked eye through dye-free ActivPerfusion™ and ActivICG™ imaging modes. The patent-protected ActiveEdge™ platform leverages augmented reality, artificial intelligence, and machine learning to improve intraoperative decision-making and address preventable surgical complications. Activ Surgical has achieved significant milestones including the world's first autonomous robotic surgery of soft tissue and CE Mark approval. With $87.5 million in funding, the company operates pilot sites in major U.S. hospital networks, addressing the critical clinical need that preventable surgical errors contribute to over 400,000 deaths annually in the U.S.

Atúlo is a multi-state home infusion services provider delivering high-quality, patient-centered infusion therapy in patients' homes. The company leverages smart technology solutions paired with clinical nursing expertise to coordinate care efficiently across multiple conditions including chemotherapy, total parenteral nutrition (TPN), and specialty infusions. Atúlo operates as a home-based alternate-site infusion provider, eliminating the need for hospital or clinic visits while maintaining clinical oversight and HIPAA compliance. The platform integrates digital health coordination with dedicated infusion nurses to improve patient comfort, independence, and clinical outcomes. Services span multiple U.S. markets with ongoing geographic expansion.

AB Sciex LLC is a global leader in mass spectrometry and capillary electrophoresis solutions for research, clinical diagnostics, and life sciences applications. The company manufactures a comprehensive portfolio of analytical instruments including triple-quadrupole and QTOF mass spectrometers, HPLC-MS systems, and capillary electrophoresis (CE) instruments. SCIEX serves clinical diagnostic laboratories with FDA-cleared in vitro diagnostic (IVD) medical devices for routine testing; pharmaceutical and biopharmaceutical companies for drug development and biologics characterization; contract research organizations for bioanalysis; environmental and food safety testing facilities; and life science research institutions. Core product lines include the Triple Quad 7500 Plus system, ZenoTOF 7600 QTOF system, Citrine clinical IVD mass spectrometers, ExionLC front-end HPLC systems, and Intabio ZT for charge variant analysis. SCIEX OS is the company's proprietary software platform supporting Windows 11 for data acquisition, processing, and instrument control. The company emphasizes speed, sensitivity, resolution, and ease of adoption across routine and complex analytical workflows. Manufacturing and support operations span multiple global regions, with primary headquarters in Marlborough, MA, and sales/service in Redwood City, CA (Americas) and multiple EMEA locations.

WatchRx is a digital healthcare platform built around smartwatch-enabled remote patient monitoring (RPM), chronic care management (CCM), transitional care management (TCM), and medication adherence solutions. The company provides an AI/ML-enabled cloud platform that integrates wearable technology to collect real-time patient vital signs and behavioral data, enabling clinicians to deliver proactive, value-based care and improve patient outcomes while reducing hospitalizations and urgent care visits. Primary markets include independent practices and primary care clinics, hospital systems, accountable care organizations (ACOs), and senior living and home care facilities. The platform automates clinical workflows, generates actionable insights for physicians, and supports medication adherence monitoring and GPS tracking for senior populations. Clinical evidence cited on the site demonstrates 76% reduction in hospitalizations, 51% reduction in urgent visits, and 90% patient satisfaction. The solution generates approximately $220+ additional revenue per patient per month through RPM/CCM billing codes. WatchRx partners with major healthcare networks and UnitedHealth Group. The company serves the growing market of value-based care delivery and remote monitoring, targeting reduction of healthcare costs and physician burnout while improving care coordination and patient engagement.

BioSensics is a wearable sensor and digital health technology company founded in 2007 by three Harvard University scientists. The company specializes in developing FDA-registered medical devices and digital biomarkers for clinical trials, remote patient monitoring, and health assessments, particularly for older adults and neurological disorders. BioSensics' core offerings include advanced fall detection and prevention systems with automatic fall alert capabilities, continuous monitoring of fall risk and physical activity, balance and gait assessment technologies, and cognitive function monitoring sensors. The company also provides the BioDigit Home platform, a centralized data aggregation system that integrates data from various digital health technologies. BioSensics has licensed its fall detection technology to major retailers and medical device manufacturers and provides comprehensive operational and technical services for clinical research across therapeutic areas including Alzheimer's disease, Parkinson's disease, and stroke. With over $50 million in NIH funding support, BioSensics has established itself as a leader in objective measurement of disease symptoms and validated biomarkers for clinical and research applications.

Miltenyi Biotec is a biotech company specializing in cell isolation, separation, and analysis technologies for research and clinical applications. The company manufactures MACS® (Magnetic Cell Separation) systems and reagents for isolating and purifying specific cell populations from complex samples. Key product lines include MicroBead Kits (e.g., StraightFrom Spleen kits for rapid immune cell isolation from mouse tissue in 15 minutes), flow cytometry instruments and software (MACSQuantify with express modes for standardized, automated workflows), and imaging analysis software (MACS iQ View 3D for large-volume image datasets). The company also offers the MACS Catalyst Program, providing guidance, instrument placement, and regulatory support (IND pathways) for cell and gene therapy developers in North America. Products target research institutions, clinical laboratories, and cell therapy manufacturers. The company supports procurement via purchase orders and maintains an online product catalog. While the fetched content does not explicitly detail FDA clearances or ISO certifications, Miltenyi Biotec is known for manufacturing life science research tools and clinical-grade cell separation systems used in regulated environments. Headquarters appear to be in Germany (Bergisch Gladbach, Rhineland) with North American operations.

Cumulus Neuroscience develops NeuLogiq®, a medical-grade, at-home digital data collection and analytics platform for functional brain health monitoring and central nervous system (CNS) disease management. The platform combines a 510(k)-cleared novel EEG headset with tablet-based cognitive, mood, language, and sleep assessments, synced to cloud-based machine learning analytics. NeuLogiq enables frequent longitudinal monitoring in clinical and home settings, designed to address challenges in CNS drug discovery including late diagnosis, patient stratification, and treatment monitoring. The company serves pharmaceutical companies conducting clinical trials through its Cumulus Pharma Advisory Group (CPAG), a paid-in consortium that includes ten major global pharmaceutical companies: Biogen, GSK, Pfizer, Eli Lilly, Takeda, Bristol Myers Squibb, Boehringer Ingelheim, Merck, Roche, and J&J Innovative Medicine. Several CPAG members have active studies using the NeuLogiq Platform. The platform assesses discrete brain functions including working memory, episodic memory, executive function, decision-making, neuronal integrity, network connectivity, emotional bias, speech characteristics, and sleep metrics. The company employs approximately 30 engineers, scientists, and business professionals, backed by experienced life science and technology investors including the Dementia Discovery Fund, as well as UK and EU innovation agencies. Regulatory clearance includes FDA 510(k) for the EEG headset. NeuLogiq integrates third-party validated algorithms for facial expression recognition, language analysis, and sleep staging.

3D Diagnostix (3DDX) is a turnkey digital dentistry provider with 20 years of experience specializing in implant planning, surgical guide fabrication, radiology report generation, and full-mouth restorative solutions. The company offers three primary workflow models: fully automated service (dentist sends scans, 3DDX handles design and manufacturing), digital flexibility (dentist plans cases using partner software, 3DDX manufactures), and all-in-office digital design services (DDS) for practices seeking complete in-house control. Core products include iPlan (implant planning software), 3D printers for chairside manufacturing, 3DDX surgical guide kits (compatible with multiple implant systems, includes fixation drills and pins), and 3DDX alignment sleeves. The company also offers iSmile clear aligners. 3DDX maintains partnerships with leading cone beam and intraoral scanner manufacturers (Planmeca, Vatech, Prexion, 3Shape, Medit, Dentsply Sirona) and serves as a guided surgery partner for major implant training institutions (Misch, Rasner Institute, Chicago Implant Institute, others). The company has processed over 300,000 dental cases and maintains a team of internally-trained dentists and technicians. All-on-X full-arch guided surgery (GFMR and GFMP protocols) is a specialty. Services include radiology report review, case planning, digital design, and manufacturing with stated fast turnaround times. 3DDX markets primarily to general dentists and implant specialists seeking to expand digital capabilities without significant capital investment or system lock-in.

VideaHealth (rebranded as Videa) is a dental AI software platform serving private dental practices, group practices, and dental support organizations. The company develops a comprehensive suite of AI-driven clinical and operational tools designed to improve diagnostics, documentation, case acceptance, and practice management workflows. The Videa Platform comprises seven integrated products: Clinical Assist (AI-assisted clinical diagnostics and decision support), Voice Notes (automated voice-to-text documentation), Daily Dashboard (practice operations and scheduling), Insights (analytics and performance metrics), Clean Claims (insurance claim optimization), and AutoVerify (insurance verification automation). The platform leverages AI to enhance caries detection, improve periodontal diagnosis, streamline treatment planning documentation, reduce clinician administrative burden, and increase case acceptance rates. Videa is trusted by over 90,000 clinicians across major dental practice networks including Heartland Dental, Dentalcorp, Aspen Dental, Comfort Dental, Sage Dental, and many independent and DSO-affiliated practices. The company emphasizes integration with existing practice workflows and has demonstrated measurable outcomes: same-store revenue growth, double-digit increases in case acceptance, improved early-stage disease detection, and reduced documentation time. The platform operates as a cloud-based software-as-a-service (SaaS) solution accessible from clinical chairs, front desks, and practice management systems. No specific FDA clearances, ISO certifications, or regulatory disclosures are mentioned on the public website.

NorthEast Monitoring is a medical device manufacturer specializing in ambulatory cardiac monitoring solutions. The company invented the world's first 14-day dual Holter and event recorder and manufactures a range of Holter recorders and event recording devices including the DR400 patch-style recorder and DR200 Holter recorder. Product offerings include both hardware (portable cardiac monitoring devices) and proprietary analysis software (HE/LX® Analysis, LX® Event, LX® Remote) designed for flexible deployment across office, hospital, and scanning service environments. The company serves physicians' offices, hospitals, and independent scanning services with solutions that streamline cardiac data collection, analysis, and remote transmission via HIPAA-compliant web portals. NorthEast Monitoring emphasizes user-friendly design, high-quality manufacturing, and an industry-leading 3-year warranty. The company has assembled a team with combined 180 years of healthcare experience across nursing, cardiology, health insurance, software engineering, and electrical engineering disciplines. Manufacturing and support capabilities include technical training videos, comprehensive documentation, and world-class customer support. Founded and led by President Mark Hubelbank Ph.D., an engineering physicist with 45 years of experience in medical research and product development in technology-based medical instrumentation.

LGC Clinical Diagnostics is a global manufacturer specializing in quality management tools, reagent components, biological materials, and diagnostic solutions for the in vitro diagnostics (IVD) and life sciences sectors. As a division of the LGC Group, the company integrates expertise from multiple brands including Technopath Clinical Diagnostics, SeraCare, Biochemical Diagnostics, Kova International, Maine Standards, and The Native Antigen Company. The company manufactures comprehensive portfolios of catalog and custom-developed diagnostic quality solutions, serving over 27,500 customers worldwide including IVD manufacturers, clinical laboratories, biopharmaceutical companies, and academic institutions. Products and services include quality controls, reference materials, linearity and calibration verification solutions, antigens and antibodies, drugs of abuse quality controls, urinalysis quality controls, and external quality assessment (EQA) proficiency testing programs. All facilities are FDA-registered and certified to ISO 13485 and ISO 9001 standards, demonstrating commitment to quality and regulatory compliance throughout the diagnostic pipeline from early research to routine clinical use.

Amphenol Alden Products Company is a precision medical cable assembly and interconnect solutions manufacturer based in Stoughton, Massachusetts. The company specializes in designing and manufacturing custom medical cable assemblies and connectors for OEM medical device manufacturers, including applications in aesthetic, electrosurgical, defibrillation, patient monitoring, X-ray, and 4K UHD imaging systems. Amphenol Alden operates global manufacturing sites across the United States, Mexico, China, and India, producing millions of assemblies annually for the top 30 medical device companies and entrepreneurial firms. Core capabilities include collaborative engineering partnerships, fine-wire termination assemblies, and comprehensive quality assurance programs. The company serves as a component supplier and manufacturing partner to medical device OEMs, providing tailored cable and connector solutions that integrate with diagnostic, surgical, monitoring, and imaging equipment. Their engineering approach emphasizes custom design, rigorous testing, and lifecycle support. While the site does not explicitly list FDA 510(k) or specific regulatory certifications, the focus on medical industry standards and quality assurance indicates compliance with medical device manufacturing requirements. Amphenol Alden positions itself as a critical infrastructure partner enabling connectivity between medical devices and healthcare facility digital ecosystems.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.

Waters Corporation is a global manufacturer of analytical laboratory instruments, consumables, software, and services headquartered in Milford, Massachusetts. The company specializes in chromatography, mass spectrometry, and sample preparation technologies for pharmaceutical, biopharmaceutical, clinical diagnostics, and life science research applications. Waters' product portfolio includes liquid chromatography (LC) and ultra-performance liquid chromatography (UPLC) systems, mass spectrometry instruments, columns, sample preparation and filtration supplies, and laboratory informatics software. Key product lines include the BioAccord System for biotherapeutic analysis, Xevo mass spectrometers for bioanalytical applications, and biphenyl columns with MaxPeak HPS technology for enhanced separation. The company serves biopharma and pharma development, clinical research and diagnostics, food and beverage testing, forensics, environmental analysis, and cannabis testing markets. Waters provides comprehensive services including instrument support, technical training, application development, and the FlexUP Technology Trade-In Program. The company recently combined with BD Biosciences and Diagnostic Solutions, and received FDA clearance for an at-home cervical cancer screening tool. Waters operates a global distribution network and maintains regulatory compliance across major markets. The company offers online shopping, customized quoting, educational resources, and multi-channel customer support.

Cardea Technology develops BoneStation, an enterprise-class, web-based software solution for DXA-based bone densitometry reporting and workflow management. BoneStation streamlines operations for bone density practices and simplifies the interpretation of bone density scans for reading physicians and radiologists. Originally developed as a custom application for a major teaching hospital, BoneStation has been commercialized and is deployed at hospitals across the United States and Europe. The company specializes in medical software development with expertise in medical imaging integration, DICOM and HL7 standards, and cloud-based application architecture. Cardea leverages modern development technologies including Java, JavaScript, SQL, and cloud platforms (Google Cloud Platform and Amazon Web Services) to deliver responsive, data-driven healthcare applications. The company combines sound software engineering principles with practical, timely software delivery for healthcare clients.

PAVmed, Inc. is a commercial-stage, diversified medical technology company focused on developing innovative diagnostics and digital health solutions. The company operates through two primary business units: Lucid Diagnostics and Veris Health. Lucid Diagnostics commercializes EsoGuard®, the first and only diagnostic test for detecting esophageal precancer and cancer, delivered via both traditional clinical settings and mobile test units. Veris Health develops a digital health platform and connected health devices for enhanced personalized cancer care through remote patient monitoring. PAVmed operates a shared-services business model that enables economies of scale across its subsidiaries. The company demonstrates clinical commitment through partnerships including participation in CancerX, a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society. Products are positioned for healthcare systems, clinicians, and patients across device, diagnostics, and digital health sectors. Recent press activity indicates ongoing expansion of medical device portfolio and continued commercialization efforts. The company maintains investor relations presence and actively engages in disease awareness initiatives such as firefighter screening programs for esophageal precancer detection.

Elevaris Medical Devices is a Contract Development and Manufacturing Organization (CDMO) specializing in precision medical device development and manufacturing. Formed from the merger of Spectra Medical Devices and XL Precision Technologies, the company combines engineering expertise with advanced manufacturing capabilities in precision micro-components, complex tubular components, and sub-assemblies. Elevaris is recognized as one of the world's leading manufacturers of made-to-spec procedural needles, including epidural, spinal, echogenic, Huber, and FNA biopsy needles. The organization provides comprehensive services including engineering design, contract development, precision manufacturing, cleanroom assembly, and regulatory compliance support. With over 300 employees across facilities in North America, the UK, and South Korea, and serving 200+ clients globally with 30 years of combined experience, Elevaris supports multinational healthcare companies, OEMs, startups, and emerging technology firms. Manufacturing capabilities include laser technology, micro-machining, injection molding, precision forming, grinding, insert molding, metal finishing, and cleanroom assembly. The company is FDA-registered, ISO 13485:2016 certified, and maintains Class 7 cleanroom facilities.

MyCareTeam develops MCT-Diabetes, a comprehensive diabetes monitoring and management platform designed to improve health outcomes and reduce overall healthcare costs. The solution facilitates communication and real-time monitoring between patients, caregivers, and healthcare professionals, enabling better disease management between clinical visits. MCT-Diabetes is marketed to three primary user groups: family caregivers seeking to support loved ones with diabetes regardless of location; healthcare professionals aiming to enhance patient quality of life through inter-visit monitoring and engagement; and organizations incorporating diabetes management into corporate wellness and employee health programs. The platform is offered on flexible monthly and yearly subscription models, making it accessible for individual and enterprise-level adoption.

MedMinder is a comprehensive digital healthcare platform specializing in medication adherence and connected care solutions for elderly patients, individuals with chronic illnesses, and those with cognitive or developmental impairments. Founded in 2007 and headquartered in Norwood, Massachusetts, the company provides an integrated ecosystem combining smart hardware, cloud-based software, pharmacy services, and remote monitoring capabilities. The MedMinder smart pill dispenser automates medication organization and delivery while generating actionable digital insights. The platform includes a user-friendly mobile app, secure cloud infrastructure, full-service digital pharmacy with prescription synchronization, and personalized data analytics. MedMinder serves providers, payors, and caregivers, enabling real-time medication tracking, remote monitoring, caregiver notifications, and improved communication between patients and clinical teams. The solution reduces medication errors, enhances medication compliance, supports independent living, and streamlines provider workflows while driving value-based care outcomes.

Implicity is a cloud-based digital MedTech software company specializing in AI-driven remote cardiac monitoring and research solutions for healthcare providers. Founded in 2016, the platform centralizes and standardizes cardiac implantable electronic device (CIED) data from multiple manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, Microport) into a single unified dashboard. The FDA-cleared, CE-marked platform employs patented AI algorithms to filter clinical alerts, reduce false positives by up to 79%, and prioritize clinically relevant events for faster clinical decision-making. Key solutions include vendor-neutral CIED remote monitoring, ILR ECG Analyzer (for Medtronic implantable loop recorders), AF Alert Management, SignalHF Predictive AI for heart failure risk stratification, and advanced research tools for real-time clinical data collection. The platform demonstrates proven clinical impact: 26% reduction in mortality, 4% reduction in hospitalization length, and 85% reduction in unnecessary atrial fibrillation alerts. Implicity serves over 100,000 patients across more than 250 medical facilities in the United States and Europe, with offices in Cambridge, Massachusetts, and Paris, France.

KBMO Diagnostics is a clinical laboratory specializing in advanced diagnostic testing for food sensitivities and gut health. The company offers the FIT (Food Inflammation Test), a patented, multi-pathway delayed food sensitivity test that measures both IgG antibodies and immune complexes—the primary food-related immune pathways. KBMO's tests are designed for healthcare providers to identify food reactivities that contribute to inflammation, autoimmune conditions, and chronic diseases including skin rashes, intestinal disorders, brain fog, and arthritis. The company provides fingerstick bloodspot collection kits for at-home testing, comprehensive personalized reports, and practitioner tools including rotation diet recommendations and integration with supplement dispensing platforms (Fullscript). KBMO also offers complementary protocols (NutriDyn, Microbiome, Biotics) to support clinical outcomes. Services target functional medicine practitioners, naturopaths, nutritionists, and chiropractors seeking actionable patient data for personalized therapeutic interventions.

Etiometry, Inc. is a Boston-based medical technology company specializing in AI-driven clinical decision-support software for intensive care units (ICUs). The Etiometry Platform (T3 Platform) aggregates real-time patient data from bedside monitors, peripheral devices, and EHR systems into a unified dashboard powered by Bayesian models and proprietary AI algorithms. The platform computes personalized risk indices to enable proactive care management in both pediatric and adult critical care settings. Core features include data aggregation and visualization, risk analytics for hemodynamic and respiratory management, automated clinical pathway workflows aligned with hospital protocols, and quality improvement analytics. The platform has received 11 FDA 510(k) clearances and CE marking, and has been deployed across 150+ clinical studies leveraging 150+ million hours of de-identified patient data. Clinical evidence demonstrates up to 36% reduction in length of stay, 41% decrease in ICU readmissions, 30% reduction in mechanical ventilation time, and 29% shorter vasoactive infusion duration. Trusted by leading academic medical centers and top-ranked children's hospitals across North America, Europe, and Asia.

Vistapath Biosystems is a software-focused medical technology company headquartered in Cambridge, MA. The company develops Sentinel, an end-to-end digital grossing platform designed to modernize pathology laboratory workflows. Sentinel automates and optimizes critical lab processes including tissue specimen grossing, enhancing quality, efficiency, and consistency across commercial laboratories, hospital pathology labs, contract research organizations (CROs), and life sciences companies. The platform leverages artificial intelligence to streamline intraoperative and routine pathology operations. Vistapath collaborates with established diagnostic and pathology partners (PathAI, Gestalt Diagnostics, PathGroup, Freedom Pathology Laboratories) to validate and deploy the Sentinel platform across clinical and research settings. The company targets mid- to large-scale pathology operations seeking digitization and workflow automation. Management includes CEO Tim Spong and VP Sales & Marketing J. Fernando Corredor, who brings over 20 years of medical device industry experience including work with acquired companies (Medtronic, Integra LifeSciences, Samsung) in imaging and AI-driven diagnostics. While regulatory certifications are not explicitly mentioned in available materials, the company's clinical deployment trajectory and partnership with established pathology networks indicate compliance with relevant healthcare software standards.

Delsys Inc. is a 30-year-old Massachusetts-based manufacturer of advanced wearable electromyography (EMG) systems and sensors for research, clinical diagnostics, and rehabilitation. The company specializes in wireless, real-time surface EMG technology with proprietary sensor designs and communication protocols optimized for human movement analysis, motor control research, neuromuscular physiology, and neurorehabilitation applications. Their primary product line—Trigno—comprises multiple system configurations (Centro for research-grade applications, Lite for entry-level systems, Link for integrated multimodal data acquisition, and HDsEMG for high-density motor unit analysis). Individual EMG sensors (Avanti, Mini, Duo, Quattro, Snap Lead) and auxiliary modules (Analog Adapter, FSR Adapter, Goniometer, Load Cell, EKG Biofeedback) enable customizable system builds. High-density EMG sensors (Galileo, Maize) support advanced motor unit decomposition and motor control studies. The Trigno ecosystem integrates with external research tools via a documented API and proprietary software (EMGworks, Trigno Discover, NeuroMap). Delsys serves academic institutions, medical research labs, rehabilitation facilities, exoskeleton/wearable robotics developers, and clinical diagnostics centers globally. Products emphasize low-noise signal acquisition, 40+ meter wireless range, intuitive data visualization and analysis workflows, and expandable architecture. The company provides remote and on-site training, technical support, and system integration services.

Hemanext Inc. is a medical technology company based in Lexington, Massachusetts, specializing in advanced blood preservation and transfusion medicine solutions. The company's flagship product, Hemanext ONE®, is an FDA-authorized oxygen-controlled processing and storage system designed to preserve red blood cell (RBC) quality during refrigerated storage for up to 42 days. By removing and maintaining low oxygen levels throughout storage, Hemanext ONE® reduces oxidative storage lesions—progressive metabolic and structural damage that degrades RBC function and oxygen delivery capacity. The system preserves critical RBC parameters including membrane integrity, deformability, and metabolic stability, resulting in higher-quality blood products that maintain closer-to-physiological function. This innovation is particularly valuable for chronic transfusion patients (such as those with sickle cell disease) requiring lifelong transfusions, as well as trauma and resuscitation settings where blood quality directly impacts clinical outcomes. Hemanext operates on a consumable model facilitating seamless integration into existing hospital and blood center workflows, with CMS reimbursement recognition reflecting the clinical and economic value of oxygen-controlled RBC units.

UltraSight is an Israeli digital health company specializing in AI-powered cardiac ultrasound imaging software. The platform provides real-time guidance and quality assessment to enable healthcare professionals of any sonography proficiency level to consistently perform high-quality cardiac ultrasound acquisitions at the point of care—in clinics, community hospitals, ambulances, and remote/rural areas. The software integrates with ultrasound devices (including Philips Lumify) and complies with healthcare standards (HL7, DICOM). UltraSight has achieved FDA clearance and CE Mark certification. The solution addresses critical clinical needs in emergency medicine, out-of-hospital care, critical care monitoring, and resource-limited settings, democratizing access to cardiac imaging while improving diagnostic accuracy and reducing repeat procedures. Clinical evidence demonstrates that novice users achieve diagnostic-quality images approaching expert sonographer performance following minimal training.

Heidelberg Engineering GmbH is a global leader in ophthalmic imaging and data solutions, founded in 1990 and trusted by eye care professionals in over 120 countries. The company specializes in high-precision diagnostic imaging systems for anterior and posterior segment ophthalmology, coupled with integrated healthcare IT solutions optimized for eye care workflows. Core product portfolio includes SPECTRALIS (multimodal retinal imaging platform), ANTERION (anterior segment imaging platform), Heidelberg Eye Explorer (ophthalmology-specific healthcare IT), and a fully digital surgical visualization platform. These solutions enable early disease detection, visualization of subtle retinal and anterior segment changes, treatment guidance, and reproducible high-definition imaging with seamless clinical infrastructure integration. The company operates a robust global support infrastructure with multilingual service capabilities and distributes products across diverse markets including academic medical centers, private practices, and research institutions. Heidelberg Engineering operates the Heidelberg Engineering Academy, providing over 20 years of continuous clinical education, hands-on training, and on-demand learning resources for eye care professionals worldwide. The company demonstrates strong commitment to scientific innovation through collaboration with leading research institutions and participation in major ophthalmic symposia (ISS, ARVO). Manufacturing and regulatory certifications align with medical device standards for ophthalmology markets.

Bruker Corporation is a global leader in high-performance scientific instruments and analytical solutions for life sciences research and diagnostics. The company manufactures a broad portfolio of analytical instruments including nuclear magnetic resonance (NMR) spectrometers, X-ray fluorescence (XRF) spectrometers, Fourier-transform infrared (FT-IR) and Raman spectrometers, electron paramagnetic resonance (EPR) systems, and advanced microscopy platforms. Bruker's diagnostic division offers the MALDI Biotyper® and IR Biotyper® systems for microbial identification, as well as the MyGenius PRO® molecular diagnostics system for sample-to-answer PCR-based infectious disease testing. The company also provides spatial biology platforms for multi-omics analysis (DNA, RNA, protein) and light-sheet microscopy systems such as the Papilio5D for 3D cell culture imaging. Bruker serves academia, biopharma, clinical diagnostics, and industrial markets globally. Products include handheld XRF analyzers (TITAN), bench-top vacuum FT-IR spectrometers (VERTEX NEO Ultra), nanomechanical testing systems (Hysitron PI Envision), and specialty analyzers for dairy and food quality control (MOVE-T). The company maintains significant R&D capabilities and offers comprehensive customer support services, consumables, accessories, and software through the Bruker Store. Bruker operates manufacturing and R&D facilities in Billerica, Massachusetts, and globally.

SEKISUI Diagnostics is a global leader in diagnostic reagents, biochemistry products, and point-of-care testing solutions with over 40 years of industry experience. The company manufactures and supplies clinical chemistry reagents, performing over 1.8 billion tests annually worldwide. Core product lines include Clinical Chemistry reagents for laboratory analyzers, Point-of-Care Testing (POCT) solutions in multiple formats to enable rapid diagnosis in office and clinic settings, and specialty biochemical enzymes for diagnostic reagent and biosensor manufacturers. SEKISUI also provides Blood Collection Tube Raw Materials and pre-analytic systems for plasma collection tubes, serving blood collection manufacturers globally. The Metrix® COVID/Flu Test represents their molecular diagnostics portfolio, offering point-of-care detection and differentiation of SARS-CoV-2, Flu A, and Flu B with small footprint and streamlined workflow. Beyond products, SEKISUI offers Biopharma Services supporting biotherapeutic and pharmaceutical manufacturing, technical transfer, and process scale-up. The company serves core laboratories, healthcare providers, in vitro diagnostics manufacturers, and distributors. SEKISUI combines analytical accuracy with operational efficiency, positioning products for cost containment and outcome improvement across clinical settings. The organization emphasizes patient-centric diagnostic solutions and maintains comprehensive technical and educational support for laboratory and clinical professionals.

RxCap is a Boston-based provider of connected remote monitoring solutions specializing in medication adherence and patient engagement. The platform combines cellular smart medication adherence devices (smart caps, pill organizers) with cloud-based monitoring software and APIs to deliver real-time adherence insights for healthcare providers, payers, and pharmaceutical manufacturers. RxCap serves pharmacies, health plans, PBMs, and life sciences organizations by enabling scalable remote monitoring programs that help close adherence gaps, personalize interventions, and improve outcomes for patients with chronic and complex health conditions. The company offers modular products including adherence monitoring devices, proprietary data hubs, patient activation portals and mobile apps, and an API library for integration with EHR systems like Epic.